Stock Market Reviews

Read and share opinions on VIR (Vir Biotechnology, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• The Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Have Been Trimming Their Sales Forecasts
  Nov 10, 2025
• Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
  Nov 9, 2025
• Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
  Nov 7, 2025
• Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
  Nov 6, 2025
• Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
  Nov 5, 2025
• Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
  Nov 5, 2025
• Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
  Nov 3, 2025
• With 59% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing
  Oct 28, 2025
• Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
  Oct 22, 2025
• Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
  Oct 9, 2025
• Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
  Oct 9, 2025
• Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
  Oct 7, 2025
• Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
  Aug 25, 2025
• Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
  Aug 6, 2025
• Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
  Aug 6, 2025
• Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
  Aug 6, 2025
• Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
  Jul 31, 2025